Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.
Dolutegravir is an HIV medicine of the integrase inhibitor group: it blocks integrase, the enzyme HIV uses to insert its genetic material into the cell's DNA. It is a preferred part of first-line HIV treatment worldwide because it is potent and the virus rarely becomes resistant to it. It is sold as Tivicay and in combination tablets such as Triumeq, Dovato and Juluca.
Dolutegravir is cleared mainly by UGT1A1, with help from CYP3A4. People with low-activity UGT1A1 versions (such as *28/*28, the Gilbert's syndrome genotype) have somewhat higher levels, which the US FDA lists as an effect on drug levels, and studies have looked at whether this relates to sleep and nervous system side effects. Studies have also looked at ABCG2 and NR1I2. There is no CPIC or DPWG guideline.
Clinical guidelines that name a gene for Dolutegravir. They sort people into groups by the gene copies they carry.
Every published finding on gene variants and Dolutegravir. Upload your DNA file to see which of these rows apply to you.
PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.
ABCG2 rs2231142: Level 3. Metabolism/PK: HIV infectious disease. 1.
NR1I2 rs2472677: Level 3. Toxicity: adverse events, Discontinuation. 1.
Studies of how quickly the body processes this medication.
Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.
More drugs from the same category
Agenerase (Protease Inhibitors)
Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.
Content updated September 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com